Top

Published in:

01-01-2011 | Original paper

The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer

Authors: Brian L. Sprague, Amy Trentham-Dietz, Patrick L. Remington

Published in: Cancer Causes & Control | Issue 1/2011

Abstract

The striking decline in United States breast cancer incidence since 2002 has been widely attributed to a reduction in postmenopausal hormone use, yet very little analysis has been conducted to quantify the contribution of changes in hormone use to the declining trend. We used literature-based estimates of the relative risk and the changing prevalence of hormone use to estimate the impact of hormone use on the decline in breast cancer incidence between 2002 and 2003 among women aged 40–79. For the base case of a 44% decline in hormone use and a relative risk for current use of 1.5, we estimated that 43% of the decline in incidence was attributable to hormone use. By exploring a range of parameter values, we found that high, unlikely values of the relative risk (i.e., ≥ 2.25) and/or the percent decline in hormone use (i.e., ≥ 75%) would be required to account for 100% of the observed decline in breast cancer incidence. We conclude that hormone use is unlikely to account for more than half of the observed decline in breast cancer incidence between 2002 and 2003. Further efforts are needed to quantify the potential contributions of other factors, such as the plateau in screening mammography utilization.

Available only for authorised users

Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMed

Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA (2007) Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99(17):1335–1339CrossRefPubMed

Kolata G (2006) Reversing trend, big drop is seen in breast cancer. In: The New York Times. 15 December 2006

Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28CrossRefPubMed

Robbins AS, Clarke CA (2007) Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99(23):1815; author reply 1816–1817

Harris JR, Lippman ME, Veronesi U, Willett W (1992) Breast cancer (1). N Engl J Med 327(5):319–328CrossRefPubMed

Holford TR, Cronin KA, Mariotto AB, Feuer EJ (2006) Chapter 4: changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr 36:19–25PubMed

Miller BA, Feuer EJ, Hankey BF (1993) Recent incidence trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 43(1):27–41CrossRefPubMed

Chu KC, Tarone RE, Kessler LG et al (1996) Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88(21):1571–1579CrossRefPubMed

10.

Altekruse SF, Kosary CL, Krapcho M et al. (2010) SEER cancer statistics review, 1975–2007. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site

11.

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350(9084):1047–1059CrossRef

12.

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed

13.

Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K (2004) Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140(3):184–188PubMed

14.

Clarke CA, Glaser SL, Uratsu CS et al (2006) Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24(33):e49–e50CrossRefPubMed

15.

Buist DS, Newton KM, Miglioretti DL et al (2004) Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104(5 Pt 1):1042–1050CrossRefPubMed

16.

Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291(1):47–53CrossRefPubMed

17.

Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99(15):1152–1161CrossRefPubMed

18.

Robbins AS, Clarke CA (2007) Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25(23):3437–3439CrossRefPubMed

19.

Colditz GA (2007) Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res 9(4):108CrossRefPubMed

20.

Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRefPubMed

21.

SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2009 Sub (1973–2007) <Katrina/Rita Population Adjustment>—Linked to County Attributes—Total U.S., 1969–2007 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission (www.seer.cancer.gov)

22.

Beral V (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362(9382):419–427CrossRefPubMed

23.

Standard Populations (Millions) for Age-Adjustment (2007) Available at: http://seer.cancer.gov/stdpopulations/. Accessed Apr 2007

24.

Clarke CA, Glaser SL (2007) Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control 18(8):847–852CrossRefPubMed

25.

Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J (2010) The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control 21(1):83–90CrossRefPubMed

26.

Colditz GA, Hankinson SE, Hunter DJ et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332(24):1589–1593CrossRefPubMed

27.

Schairer C, Lubin J, Troisi R et al (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283(4):485–491CrossRefPubMed

28.

Kerlikowske K, Miglioretti DL, Ballard-Barbash R et al (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321CrossRefPubMed

29.

Li CI, Weiss NS, Stanford JL, Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88(11):2570–2577CrossRefPubMed

30.

Newcomb PA, Titus-Ernstoff L, Egan KM et al (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11(7):593–600PubMed

31.

Daling JR, Malone KE, Doody DR et al (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95(12):2455–2464CrossRefPubMed

32.

Stierer M, Rosen H, Weber R et al (1993) Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg 218(1):13–21CrossRefPubMed

33.

Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16(12):2773–2780CrossRefPubMed

34.

Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK (1996) Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 5(12):961–965PubMed

35.

Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93(23):1811–1817CrossRefPubMed

36.

Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4):328–332CrossRefPubMed

37.

Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918CrossRefPubMed

38.

National Center for Health Statistics: Health, United States, 2008 with chartbook

39.

CDC (2007) Use of mammograms among women aged > 40 years—United States, 2000–2005. MMWR 56:49–51

40.

Caan B, Habel L, Quesenberry C, Kushi L, Herrinton L (2008) Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 100(8):597–598; author reply 599

41.

Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90(18):1371–1388CrossRefPubMed

42.

Feuer EJ (2006) Modeling the impact of adjuvant therapy, screening mammography on U.S. breast cancer mortality between 1975 and 2000: introduction to the problem. J Natl Cancer Inst Monogr 2006(36):2–6

43.

Surveillance Epidemiology and End Results (SEER) Program: SEER*Stat database [released April 2009, based on the November 2008 submission] (www.seer.cancer.gov)

Title: The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer
Authors: Brian L. Sprague
Amy Trentham-Dietz
Patrick L. Remington
Publication date: 01-01-2011
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 1/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9682-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case–control studies in the International Lung Cancer Consortium (ILCCO)

Complementary approaches to assessing risk factors for interval breast cancer

Dietary patterns and breast cancer risk among Chinese women

Intake of heterocyclic aromatic amines and the risk of prostate cancer in the EPIC-Heidelberg cohort

Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer

Secondhand smoke exposure in bars and restaurants in Guatemala City: before and after smoking ban evaluation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer